Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Previous studies have shown activation of the immune system and altered immune response in Huntington's disease (HD) gene carriers. Here, we hypothesized that peripheral and central immune responses could be concurrent pathophysiological events and represent a global innate immune response to the toxic effects of mutant huntingtin in HD gene carriers. We sought to investigate our hypothesis using [(11)C]PK11195 PET as a translocator protein (TSPO) marker of central microglial activation, together with assessment of peripheral plasma cytokine levels in a cohort of premanifest HD gene carriers who were more than a decade from predicted symptomatic conversion. Data were also compared to those from a group of healthy controls matched for age and gender. We found significantly increased peripheral plasma IL-1β levels in premanifest HD gene carriers compared to the group of normal controls (P=0.018). Premanifest HD gene carriers had increased TSPO levels in cortical, basal ganglia and thalamic brain regions (P<0.001). Increased microglial activation in somatosensory cortex correlated with higher plasma levels of IL-1β (rs=0.87, P=0.013), IL-6 (rs=0.85, P=0.013), IL-8 (rs=0.68, P=0.045) and TNF-α (rs=0.79; P=0.013). Our findings provide first in vivo evidence for an association between peripheral and central immune responses in premanifest HD gene carriers, and provide further supporting evidence for the role of immune dysfunction in the pathogenesis of HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 4×
“We found significantly increased peripheral plasma IL-1β levels in premanifest HD gene carriers compared to the group of normal controls (P = 0.018).”
BackgroundInfluentialConsensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Adverse Effects of Modest Sleep Restriction on Sleepiness, Performance, and Inflammatory Cytokines
Vgontzas, A. N., Zoumakis, E., Bixler, E. O., Lin, H.-M., Follett, H., Kales, A., & Chrousos, G. P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031562 · Cited by 1,050
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Self-citationViviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 1×
“…have demonstrated in vivo significantmicroglial activation in the striatumand cortical regions of premanifest and manifest HD gene carriers, which was associated with loss of dopamine D2 receptors and symptom severity (Pavese et al., 2006; Tai et al., 2007; Politis et al., 2008, 2011).”
BackgroundSelf-citationMicroglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440 · cited 1×
“…have demonstrated in vivo significantmicroglial activation in the striatumand cortical regions of premanifest and manifest HD gene carriers, which was associated with loss of dopamine D2 receptors and symptom severity (Pavese et al., 2006; Tai et al., 2007; Politis et al., 2008, 2011).”
BackgroundSelf-citationIL-6 and its circadian secretion in humans
Vgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Trakada, G., & Chrousos, G. P. (2005) · Neuroimmunomodulation · doi:10.1159/000084844 · Cited by 338
Research works printed but not linked: 42
- Anderson, 2007, A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195, NeuroImage, 36, 28, 10.1016/j.neuroimage.2007.02.017 · DOI
- Björkqvist, 2008, A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease, J. Exp. Med., 205, 1869, 10.1084/jem.20080178 · DOI · Paper page
- Chang, 2015, Plasma inflammatory biomarkers for Huntington's disease patients and mouse model, Brain Behav. Immun., 44, 121, 10.1016/j.bbi.2014.09.011 · DOI
- Chen, 2000, Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat. Med., 6, 797, 10.1038/77528 · DOI · Paper page
- Craufurd, 2001, Behavioral changes in Huntington disease, Neuropsychiatry Neuropsychol. Behav. Neurol., 14, 219
- Crocker, 2006, DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations, Brain Res., 1088, 176, 10.1016/j.brainres.2006.02.102 · DOI
- Ferrante, 1997, Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum, J. Neurosci., 17, 3052, 10.1523/JNEUROSCI.17-09-03052.1997 · DOI · Paper page
- Friedlander, 1996, Functional role of interleukin 1 beta (IL-1beta) in IL-1 beta-converting enzyme-mediated apoptosis, J. Exp. Med., 184, 717, 10.1084/jem.184.2.717 · DOI · Paper page
- Gousias, 2008, Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest, NeuroImage, 40, 672, 10.1016/j.neuroimage.2007.11.034 · DOI · Paper page
- Gunn, 1997, Parametric imaging of ligand-receptor binding in PET using a simplified reference region model, NeuroImage, 6, 279, 10.1006/nimg.1997.0303 · DOI · Paper page
- Hammers, 2003, Three dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe, Hum. Brain Mapp., 19, 224, 10.1002/hbm.10123 · DOI · Paper page
- Hammers, 2007, Automatic detection and quantification of hippocampal atrophy on MRI in temporal lobe epilepsy: a proof-of-principle study, Neuroimage., 36, 38, 10.1016/j.neuroimage.2007.02.031 · DOI
- Heckemann, 2006, Automatic anatomical brain MRI segmentation combining label propagation and decision fusion, NeuroImage, 33, 115, 10.1016/j.neuroimage.2006.05.061 · DOI · Paper page
- Heckemann, 2010, Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation, NeuroImage, 51, 221, 10.1016/j.neuroimage.2010.01.072 · DOI · Paper page
- Huntington Study Group, 1996, Unified Huntington's disease rating scale: reliability and consistency, Mov. Disord., 11, 136, 10.1002/mds.870110204 · DOI · Paper page
- Kemp, 2006, NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes, J. Nucl. Med., 47, 1960
- Khoshnan, 2004, Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity, J. Neurosci., 24, 7999, 10.1523/JNEUROSCI.2675-04.2004 · DOI · Paper page
- Knudsen, 2008, Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis, Biomarkers, 13, 59, 10.1080/13547500701615017 · DOI · Paper page
- Kwan, 2012, Mutant huntingtin impairs immune cell migration in Huntington disease, J. Clin. Invest., 122, 4737, 10.1172/JCI64484 · DOI · Paper page
- Langbehn, 2004, A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length, Clin. Genet., 65, 267, 10.1111/j.1399-0004.2004.00241.x · DOI · Paper page
- McColl, 1994, Statistical methods in neuroimaging with particular application to emission tomography, Stat. Methods Med. Res., 3, 63, 10.1177/096228029400300105 · DOI
- Melton, 2003, Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA, Glia, 44, 1, 10.1002/glia.10276 · DOI · Paper page
- Montgomery, 2006, Correction of head movement on PET studies: comparison of methods, J. Nucl. Med., 47, 1936
- Nakanishi, 2003, Microglial functions and proteases, Mol. Neurobiol., 27, 163, 10.1385/MN:27:2:163 · DOI · Paper page
- Ona, 1999, Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease, Nature, 399, 263, 10.1038/20446 · DOI · Paper page
- Penney, 1997, CAG repeat number governs the development rate of pathology in Huntington's disease, Ann. Neurol., 41, 689, 10.1002/ana.410410521 · DOI · Paper page
- Politis, 2008, Hypothalamic involvement in Huntington's disease: an in vivo PET study, Brain, 131, 2860, 10.1093/brain/awn244 · DOI · Paper page
- Quarantelli, 2004, Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction, J. Nucl. Med., 45, 192
- Reilmann, 2010, Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease, Mov. Disord., 25, 2195, 10.1002/mds.23243 · DOI
- Reilmann, 2011, Assessment of involuntary choreatic movements in Huntington's disease—toward objective and quantitative measures, Mov. Disord., 26, 2267, 10.1002/mds.23816 · DOI · Paper page
- Riess, 1993, Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease, Hum. Mol. Genet., 2, 637, 10.1093/hmg/2.6.637 · DOI · Paper page
- Silvestroni, 2009, Distinct neuroinflammatory profile in postmortem human Huntington's disease, Neuroreport, 20, 1098, 10.1097/WNR.0b013e32832e34ee · DOI · Paper page
- Stroop, 1935, Studies of interference in serial verbal reactions, J. Exp. Psychol., 18, 643, 10.1037/h0054651 · DOI · Paper page
- Studholme, 1997, Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures, Med. Phys., 24, 25, 10.1118/1.598130 · DOI · Paper page
- Tabrizi, 2013, Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data, Lancet Neurol., 12, 637, 10.1016/S1474-4422(13)70088-7 · DOI · Paper page
- Träger, 2014, HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation, Brain, 137, 819, 10.1093/brain/awt355 · DOI · Paper page
- Trottier, 1995, Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form, Nat. Genet., 10, 104, 10.1038/ng0595-104 · DOI · Paper page
- Troy, 1996, The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation, Proc. Natl. Acad. Sci. U. S. A., 93, 5635, 10.1073/pnas.93.11.5635 · DOI · Paper page
- Turkheimer, 1999, Multiresolution analysis of emission tomography images in the wavelet domain, J. Cereb. Blood Flow Metab., 19, 1189, 10.1097/00004647-199911000-00003 · DOI · Paper page
- Turkheimer, 2007, Reference and target region modeling of [11C]-(R)-PK11195 brain studies, J. Nucl. Med., 48, 158
- Warner, 1993, A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes, Mol. Cell. Probes, 7, 235, 10.1006/mcpr.1993.1034 · DOI · Paper page
- Yaqub, 2012, Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies, J. Cereb. Blood Flow Metab., 32, 1600, 10.1038/jcbfm.2012.59 · DOI · Paper page
Cited by
Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E., & Leavitt, B. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00121-1 · Cited by 331
Self-citationWerry, E. L., Bright, F. M., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kril, J. J., & Kassiou, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133161 · Cited by 279
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“We hypothesize that these genetics and thus clinical features could explain the difference in microglial activation, objectified by ventral striatum TSPO tracer binding variability in premanifest HD patients [88,89].”
BackgroundTSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward
Guilarte, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.003 · Cited by 173
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
“…(Silvestroni et al., 2009) TNF-α Primary glial cells isolated from R6/2; Plasma and CSF from HD patient (Bjorkqvist et al., 2008) Plasma of HD patient (Politis et al., 2015) CCL2 Chemokine Post-mortem brain of HD patient (Silvestroni et al., 2009) MMP-9 Extracellular proteins Post-mortem brain of…”
BackgroundMethodInfluential
Metadata
- Authors
- Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F. E., Tabrizi, S. J., & Piccini, P.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 83
- Pages
- 115-121
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1149926701
- Cited by
- 153
- References
- 14
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-02-01)
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Cure Huntington's Disease Initiative Foundation
- Parkinson's UK
- Edmond J. Safra Foundation
- Michael J Fox Foundation
- NIHR BRC
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. https://app.cochat.ai/papers/10.1016/j.nbd.2015.08.011
- The paper
- Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F. E., Tabrizi, S. J., & Piccini, P. (2015). Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2015.08.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.